In this regard, a meta-analysis of 17 preclinical studies on AD animal models revealed that EGCG exerts neuroprotective effects by reducing acetylcholinesterase activity, enhancing α-, β-, and γ-secretase activity, decreasing Aβ42 levels and tau phosphorylation, and modulating anti-oxidative, anti-inflammatory, and anti-apoptotic processes [146]. This evidence concerns the gene MAPT and Alzheimer disease.